



DEREK LIU

Counsel · Beijing

+86 10 5769 4243

derek.liu@fangdalaw.com

PRACTICE AREA

DEREK SPECIALIZES IN ADVISING CLIENTS ON COMPLEX COMPETITION LAW AND NATIONAL SECURITY REVIEW MATTERS ARISING FROM CROSS-BORDER MERGERS, ACQUISITIONS, AND JOINT VENTURES. HE ALSO REGULARLY REPRESENTS CLIENTS IN ANTITRUST-RELATED GOVERNMENT INVESTIGATIONS AND CIVIL LITIGATION AND ASSISTS THEM IN IMPROVING THEIR ANTITRUST COMPLIANCE.

Education

- Peking University Law School, LL.B. (2018)
- Peking University National School of Development, B.A. in Economics (2018)

Professional Qualification

- Admitted to practice in the PRC

Professional Background

- Derek joined Fangda in 2021. Before that, he worked in the compliance and government enforcement practice of another leading PRC law firm, where he also developed his expertise in cybersecurity and trade control matters.

REPRESENTATIVE MATTERS AND CASES

Merger filings, governmental investigations and civil litigations

- Advised Warburg Pincus, Blackstone, Macquarie, TPG, TA Associates, Sequoia Capital, etc. on the PRC merger filings for their global alternative investment transactions
- Advised SQM on the PRC merger filing for its proposed public-private partnership with Codelco for lithium development at Atacama and on the implementation of the behavioral remedies imposed by SAMR
- Advised TCL CSOT on the PRC merger filing for its acquisition of LG Display's LCD panel business in China and coordinated the merger filings across six jurisdictions: South Korea, Vietnam, Poland, Turkey, Mexico, and Egypt
- Advised Envision Energy on coordinating the merger filings for its joint venture with Saudi Public Investment Fund and Vision Industries in the wind turbine sector across four jurisdictions: Saudi Arabia, Egypt, Morocco, and COMESA
- Advised AstraZeneca on the PRC merger filing for its acquisition of entire commercial rights in China for Roxadustat (an innovative drug for treating CKD-anemia)
- Advised Emerson on the PRC merger filing for its acquisition of National Instruments
- Advised DuPont on the PRC merger filing for divesting its majority stake in Mobility & Materials Segment to Celanese
- Advised Swire on the PRC merger filing for the restructuring of Coca-Cola's still beverage production facilities in China
- Advised Mitsui on the PRC merger filing for its acquisition of Derit seed company
- Advised ONE on the PRC merger filings for its acquisitions of two cargo terminals on the US west coast
- Advised Cargill on the PRC merger filing for divesting its China poultry business to DCP Capital
- Advised JiamianTech on the CAC review and PRC merger filing for its joint venture with Netease
- Advised Rosewood Hotel on the PRC merger filing for establishing a joint venture with Trip.com
- Advised Luxottica on the PRC merger filing for its merger with Essilor and on the implementation of the

behavioral remedies imposed by SAMR

- Advised Bombardier Transportation on the PRC merger filing for its sale of its transportation business to Alstom*
- Advised Yum! China on the PRC merger filing for its joint venture with Mininglamp, which was the first unconditional clearance by the PRC antitrust regulator involving a VIE structure and has stood as a milestone in PRC antitrust law enforcement in the internet and digital platform sectors since 2020*
- Advised a German automotive manufacturer on responding to SAMR's antitrust inquiries on vertical restraints
- Advised a German automotive manufacturer on responding to SAMR's antitrust investigation into the manufacturer's potential participation in a worldwide cartel
- Advised Straumann on responding to the Beijing Administration for Market Regulation's antitrust investigation into Straumann's Chinese subsidiary
- Represented Qualcomm in Beijing Intellectual Property Court in responding to Apple's antitrust and FRAND lawsuits relating to its 3G/4G SEP license*
- Advised a high-tech company on commencing antitrust lawsuits in the Chinese courts against an NPE entity

* Including the works prior to joining Fangda.

National Security Review

- Advised New China Insurance on FDI screening risk analysis for its overseas investments in a US dollar fund focused on the medical and healthcare sectors
 - Advised a Japanese trade house on the PRC national security review filing for its acquisition of a Chinese seed development company
 - Advised a US industrial technology company on the PRC national security review filing for its acquisition of a US testing and measurement company and persuaded the PRC authority not to initiate a formal review
 - Advised a US chemical company on the pre-filing consultation for its PRC national security review for its establishment of a lithium processing joint venture with an Australian lithium mining company
 - Advised a leading global investment company on the PRC national security review filing for acquiring an operator of pharmacy chains in China
 - Advised a leading global alternative investment management company on the pre-filing consultation for its PRC national security review and on the subsequent filing for its acquisition of a leading Chinese office developer
 - Advised a consortium of several US funds and the Founders on the pre-filing consultation for their PRC national security review in their take-private transaction of a NASDAQ-listed company
 - Advised a Japanese industrial company on the PRC national security review for its several public tenders over Japanese targets
 - Advised a Japanese producer of consumer and industrial electric products on the PRC national security review for its privatization transaction
 - Advised Blackstone, KKR, BPEA EQT, Sequoia Capital, and Hillhouse Capital on PRC national security reviews for their direct and indirect investments and their M&A transactions in China
-